Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 219.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.56 mL||22.81 mL||45.61 mL|
|5 mM||0.91 mL||4.56 mL||9.12 mL|
|10 mM||0.46 mL||2.28 mL||4.56 mL|
|50 mM||0.09 mL||0.46 mL||0.91 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Isaacson and Nicholl (1991) Aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 88 10936 PMID: 1660156
Ito et al (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J.Physiol. 424 553 PMID: 1975272
Nakamura and Kurasawa (2001) Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur.J.Pharmacol. 420 33 PMID: 11412837
If you know of a relevant reference for Aniracetam, please let us know.
View Related Products by Product Action
Keywords: Desensitization inhibitors inhibits AMPA kainate Glutamate Receptors iGluR Ionotropic allosteric modulators potentiators AMPA Receptors
Citations for Aniracetam
Citations are publications that use Tocris products.
Currently there are no citations for Aniracetam. Do you know of a great paper that uses Aniracetam from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.